[New therapeutic targets in testicular cancer: contribution of molecular biology].
Testicular cancer is curable by conventional cytotoxic drugs. Despite these excellent results, a group of patients remain incurable with standard chemotherapy, including patients who progress despite high-dose salvage chemotherapy, patients with malignant transformation of teratomas and patients with late recurrence. Tyrosine kinase receptors constitute a group of proteins which includes EGFr (Epidermal Growth Factor receptor) and c-Kit. The recent possibility of treatments targeted to the molecular level, particularly using agents directed against c-Kit and EGFr raise new hopes for the effective treatment of refractory testicular cancer.
Paule
Bernard
B
Service d'Urologie, Hôpital Henri Mondor Créteil, France. bepaule@wanadoo.fr
D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D008967:Molecular Biology; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects; D013736:Testicular Neoplasms / Q000188:drug therapy*
D066246:ErbB Receptors; D019009:Proto-Oncogene Proteins c-kit